82720-44-3

Upstream product

• 501-53-1 benzyl chloroformate 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 16492-11-8 4-methyl-9-chloroacridine 
• 86187-37-3 dimethyl N-(4-amino-3-methoxyphenyl)phosphoramidate 

Downstream Products

• 82720-45-4 benzyl N-(4-amino-2-methoxy-phenyl)carbamate 
• 82720-41-0 [4-(Acridin-9-ylamino)-3-methoxy-phenyl]-phosphoramidic acid dimethyl ester 
• 86187-36-2 dimethyl N-<4-<(benzyloxy)carboxamido>-3-methoxyphenyl>phosphoramidate 
• 86187-37-3 dimethyl N-(4-amino-3-methoxyphenyl)phosphoramidate 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

Certain acridinyl-phosphoramidate compounds

The novel class of compounds of the present invention represented by the general formula (I): STR1 in which R1 represents H or OCH3, R2 represents H, OCH3, CH3, halogen, NO2, NH2, NHCOCH3 or NHCOOCH3, and R3 and R4 individually represent H, CH3, OCH3 or CONHCH3, and the acid addition salts thereof, have unexpectedly high potency and activity in in vivo antitumour tests. The compounds are also bacteriostatic, and show toxicity towards mouse, hamster and human tumour cell lines in culture.